Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles

被引:21
作者
Glowka, Eliza [1 ,2 ]
Sapin-Minet, Anne [1 ]
Leroy, Pierre [1 ]
Lulek, Janina [2 ]
Maincent, Philippe [1 ]
机构
[1] Nancy Univ, Lab Pharmaceut Technol & Biopharm, Fac Pharm, F-54001 Nancy, France
[2] Poznan Univ Med Sci, Dept Pharmaceut Technol, Fac Pharm, Poznan, Poland
关键词
Salmon calcitonin; nanoparticles; peptide stability; sustained release; bioavailability; LOW-MOLECULAR-WEIGHT; SUSTAINED-RELEASE; ORAL DELIVERY; MICROSPHERES; POLY(D; L-LACTIDE-CO-GLYCOLIDE); ADSORPTION; OSTEOPOROSIS; DEGRADATION; STABILITY; PEPTIDES;
D O I
10.3109/02652040902751125
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The aim of the study was to develop and characterize polymeric nanoparticles as a sustained release system for salmon calcitonin (sCT). Nanoparticles were prepared by a double emulsion solvent evaporation method using Eudragit (R) RS and two types of a biodegradable poly(lactic-co-glycolic) copolymer (PLGA). It was demonstrated that sCT was incorporated into nanoparticles with encapsulation efficiencies in the range 69-83%. In vitro release studies, unconventionally conducted in 5% acetic acid, showed great differences in sCT release time profiles. Nanoparticles with fast release profile (Eudragit (R) RS, PLGA/Eudragit (R) RS) released 80-100% of the encapsulated drug within a few hours. In contrast, the sCT release from pure PLGA nanoparticles was very slow, incomplete and reached only 20% after 4 weeks. In vivo study, conducted in Wistar rats, proved that elevated serum sCT levels could be sustained for 3 days after subcutaneous administration of PLGA nanoparticles and the achieved bioavailability was increased compared to sCT solution.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 31 条
  • [1] Calcitonin release system in the treatment of experimental osteoporosis. Histomorphometric evaluation
    Aldini, NN
    Caliceti, P
    Lora, S
    Fini, M
    Giavaresi, G
    Rocca, M
    Torricelli, P
    Giardino, R
    Veronese, FM
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2001, 19 (05) : 955 - 961
  • [2] Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
    Blanco, MD
    Alonso, MJ
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (03) : 287 - 294
  • [3] Importance of the test medium for the release kinetics of a somatostatin analogue from poly(D,L-lactide-co-glycolide) microspheres
    Blanco-Príeto, MJ
    Besseghir, K
    Orsolini, P
    Heimgartner, F
    Deuschel, C
    Merkle, HP
    Hô, NT
    Gander, B
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 184 (02) : 243 - 250
  • [4] Body JJ, 2002, BONE, V30, p75S
  • [5] Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification-solvent evaporation
    Chernysheva, YV
    Babak, VG
    Kildeeva, NR
    Boury, F
    Benoit, JP
    Ubrich, N
    Maincent, P
    [J]. MENDELEEV COMMUNICATIONS, 2003, (02) : 65 - 68
  • [6] Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats
    Damge, Christiane
    Maincent, Philippe
    Ubrich, Nathalie
    [J]. JOURNAL OF CONTROLLED RELEASE, 2007, 117 (02) : 163 - 170
  • [7] Dani BA, 2001, AAPS PHARMSCI, V3
  • [8] One-month sustained release microspheres of 125I-bovine calcitonin -: In vitro in vivo studies
    Diaz, RV
    Llabrés, M
    Évora, C
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 59 (01) : 55 - 62
  • [9] Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles
    Dillen, Kathleen
    Vandervoort, Jo
    Van den Mooter, Guy
    Ludwig, Annick
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 314 (01) : 72 - 82
  • [10] In vitro and in vivo characterization of huperzine A loaded microspheres made from end-group uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid)
    Gao, P
    Ding, PT
    Xu, H
    Yuan, ZT
    Chen, DW
    Wei, L
    Chen, D
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2006, 54 (01) : 89 - 93